+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neuroprotection Market by Product Type (Biologics, Drugs, Gene Therapy), Mechanism Of Action (Anti Inflammatory Agents, Antioxidants, Calcium Channel Blockers), End User, Indication, Distribution Channel - Global Forecast 2025-2030- Product Image
Neuroprotection Market by Product Type (Biologics, Drugs, Gene Therapy), Mechanism Of Action (Anti Inflammatory Agents, Antioxidants, Calcium Channel Blockers), End User, Indication, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Neuroprotection Market by Product Type (Biologics, Drugs, Gene Therapy), Mechanism Of Action (Anti Inflammatory Agents, Antioxidants, Calcium Channel Blockers), End User, Indication, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4857892
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior executives seeking clarity on strategic opportunities in the neuroprotection industry will find this comprehensive market analysis indispensable. The neuroprotection market is becoming increasingly influential in addressing the rise of neurological disorders and advancing patient care standards across diverse therapeutic landscapes.

Market Snapshot: Neuroprotection Market Overview

The neuroprotection market grew from USD 311.79 billion in 2024 to USD 336.31 billion in 2025. It is expected to continue growing at a CAGR of 7.72%, reaching USD 487.27 billion by 2030. This growth highlights accelerating demand for advanced neurological therapeutics as global demographics shift and disease incidence increases. The primary keyword, “neuroprotection market,” reflects the sector’s critical position in delivering new solutions for degenerative and acute neurological conditions. Market growth is driven by ongoing innovations, policy adjustments, and collaborative advancements among industry leaders.

Scope & Segmentation

This report categorizes the neuroprotection market across multiple parameters to ensure decision-makers can target key growth areas:

  • Product Types: Biologics (monoclonal antibody and neurotrophic factor biologics), peptide drugs, small molecule drugs, gene therapy, nutraceuticals (herbal extracts, minerals, vitamins), stem cell therapy.
  • Mechanisms of Action: Anti-inflammatory agents (cytokine inhibitors, NSAIDs, steroids), antioxidants (flavonoids, vitamin C, vitamin E), calcium channel blockers (flunarizine, nimodipine), glutamate inhibitors, neurotrophic factors, NMDA antagonists (ketamine, memantine).
  • End Users: Clinics, home healthcare, hospitals, research institutes.
  • Indications: Alzheimer’s disease (early, moderate, severe), multiple sclerosis (relapsing-remitting, secondary progressive), Parkinson’s disease (postural instability, tremor dominant), spinal cord injury, stroke (hemorrhagic, ischemic), traumatic brain injury.
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies.
  • Regions Covered: Americas (with major U.S. states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (U.K., Germany, France, and several others), Asia-Pacific (China, India, Japan, Australia, South Korea, and more).
  • Major Companies Profiled: Eli Lilly and Company, Roche Holding AG, Novartis AG, AstraZeneca PLC, Biogen Inc., Pfizer Inc., AbbVie Inc., Johnson & Johnson, Merck & Co., Inc., GlaxoSmithKline plc.

Key Takeaways: Strategic Insights for Decision-Makers

  • The market’s expansion is fueled by a convergence of scientific advancements, adaptive regulatory policies, and industry-wide collaboration.
  • Biologic therapies, gene editing, and novel nutraceuticals are setting new directions for disease-modifying treatments, enhanced by targeted delivery mechanisms and biomarker-driven patient segmentation.
  • Digital therapeutics and remote monitoring technologies are reshaping patient management, enabling earlier interventions and personalized dosing.
  • Organizations are evolving their market entry strategies to reflect regional differences in healthcare infrastructure, reimbursement models, and payer expectations.
  • Innovation pipelines and alliances—both among leading pharmaceutical companies and with technology partners—are crucial for maintaining clinical, regulatory, and cost competitiveness.

Tariff Impact: Navigating 2025 U.S. Regulatory Changes

The introduction of United States tariffs in 2025 has changed cost structures for manufacturers and distributors of neuroprotective therapeutics. Increased import duties on raw materials and active ingredients sourced internationally have prompted organizations to explore nearshoring, dual-sourcing, and regional manufacturing within tariff-exempt zones. Stakeholders are also renegotiating supply contracts, adopting cost-sharing mechanisms, and enhancing inventory management to offset the effects. This dynamic regulatory environment requires robust scenario planning and risk modeling capabilities to remain agile and sustain profitability across the value chain.

Methodology & Data Sources

This report employs a rigorous research methodology, combining primary interviews with neurologists, pharmacologists, regulatory experts, and payers, as well as comprehensive secondary research from journals, filings, and databases. Validation utilizes quantitative analysis and thematic coding, alongside regular expert review cycles, to ensure the highest standards of accuracy and actionable insight.

Why This Report Matters

  • Senior leaders will gain strategic clarity to target high-potential market segments, emerging technologies, and regional opportunities with confidence.
  • The report delivers a holistic, data-backed foundation for risk mitigation, partnership formation, and long-term commercial planning in complex and evolving neuroprotection markets.

Conclusion

This neuroprotection market analysis equips decision-makers with the insights necessary to navigate technological advances and shifting policy environments. Targeted strategies and evidence-based recommendations support robust, future-focused business outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of gene editing therapies targeting neuroinflammation pathways in multiple sclerosis patients
5.2. Adoption of wearable neurostimulation devices for personalized management of chronic migraine symptoms
5.3. Integration of AI-driven biomarkers for early Alzheimer’s disease diagnosis and progression monitoring
5.4. Development of blood-brain barrier-penetrant small molecules for acute ischemic stroke intervention
5.5. Rising investment in cell-based therapies harnessing neural stem cells for spinal cord injury repair
5.6. Utilization of lipid nanoparticle platforms for RNA-based neuroprotective treatment in Parkinson’s disease
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Neuroprotection Market, by Product Type
8.1. Introduction
8.2. Biologics
8.2.1. Monoclonal Antibody Biologics
8.2.2. Neurotrophic Factor Biologics
8.3. Drugs
8.3.1. Peptide Drugs
8.3.2. Small Molecule Drugs
8.4. Gene Therapy
8.5. Nutraceuticals
8.5.1. Herbal Extract Nutraceuticals
8.5.2. Mineral Nutraceuticals
8.5.3. Vitamin Nutraceuticals
8.6. Stem Cell Therapy
9. Neuroprotection Market, by Mechanism Of Action
9.1. Introduction
9.2. Anti Inflammatory Agents
9.2.1. Cytokine Inhibitor Anti Inflammatory Agents
9.2.2. NSAID Anti Inflammatory Agents
9.2.3. Steroid Anti Inflammatory Agents
9.3. Antioxidants
9.3.1. Flavonoid Antioxidants
9.3.2. Vitamin C Antioxidants
9.3.3. Vitamin E Antioxidants
9.4. Calcium Channel Blockers
9.4.1. Flunarizine Calcium Channel Blockers
9.4.2. Nimodipine Calcium Channel Blockers
9.5. Glutamate Inhibitors
9.6. Neurotrophic Factors
9.7. NMDA Antagonists
9.7.1. Ketamine NMDA Antagonists
9.7.2. Memantine NMDA Antagonists
10. Neuroprotection Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Home Healthcare
10.4. Hospitals
10.5. Research Institutes
11. Neuroprotection Market, by Indication
11.1. Introduction
11.2. Alzheimer's Disease
11.2.1. Early Stage Alzheimer's Disease
11.2.2. Moderate Stage Alzheimer's Disease
11.2.3. Severe Stage Alzheimer's Disease
11.3. Multiple Sclerosis
11.3.1. Relapsing Remitting Multiple Sclerosis
11.3.2. Secondary Progressive Multiple Sclerosis
11.4. Parkinson's Disease
11.4.1. Postural Instability Parkinson's Disease
11.4.2. Tremor Dominant Parkinson's Disease
11.5. Spinal Cord Injury
11.6. Stroke
11.6.1. Hemorrhagic Stroke
11.6.2. Ischemic Stroke
11.7. Traumatic Brain Injury
12. Neuroprotection Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas Neuroprotection Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Neuroprotection Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Neuroprotection Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Eli Lilly and Company
16.3.2. Roche Holding AG
16.3.3. Novartis AG
16.3.4. AstraZeneca PLC
16.3.5. Biogen Inc.
16.3.6. Pfizer Inc.
16.3.7. AbbVie Inc.
16.3.8. Johnson & Johnson
16.3.9. Merck & Co., Inc.
16.3.10. GlaxoSmithKline plc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. NEUROPROTECTION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. NEUROPROTECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. NEUROPROTECTION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. NEUROPROTECTION MARKET: RESEARCHAI
FIGURE 26. NEUROPROTECTION MARKET: RESEARCHSTATISTICS
FIGURE 27. NEUROPROTECTION MARKET: RESEARCHCONTACTS
FIGURE 28. NEUROPROTECTION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NEUROPROTECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEUROPROTECTION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NEUROPROTECTION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NEUROPROTECTION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NEUROPROTECTION MARKET SIZE, BY MONOCLONAL ANTIBODY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTOR BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NEUROPROTECTION MARKET SIZE, BY PEPTIDE DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NEUROPROTECTION MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NEUROPROTECTION MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NEUROPROTECTION MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NEUROPROTECTION MARKET SIZE, BY HERBAL EXTRACT NUTRACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NEUROPROTECTION MARKET SIZE, BY MINERAL NUTRACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN NUTRACEUTICALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NEUROPROTECTION MARKET SIZE, BY CYTOKINE INHIBITOR ANTI INFLAMMATORY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NEUROPROTECTION MARKET SIZE, BY NSAID ANTI INFLAMMATORY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NEUROPROTECTION MARKET SIZE, BY STEROID ANTI INFLAMMATORY AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLAVONOID ANTIOXIDANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN C ANTIOXIDANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NEUROPROTECTION MARKET SIZE, BY VITAMIN E ANTIOXIDANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NEUROPROTECTION MARKET SIZE, BY FLUNARIZINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NEUROPROTECTION MARKET SIZE, BY NIMODIPINE CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NEUROPROTECTION MARKET SIZE, BY GLUTAMATE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NEUROPROTECTION MARKET SIZE, BY NEUROTROPHIC FACTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL NEUROPROTECTION MARKET SIZE, BY KETAMINE NMDA ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL NEUROPROTECTION MARKET SIZE, BY MEMANTINE NMDA ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL NEUROPROTECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL NEUROPROTECTION MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL NEUROPROTECTION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL NEUROPROTECTION MARKET SIZE, BY EARLY STAGE ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL NEUROPROTECTION MARKET SIZE, BY MODERATE STAGE ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL NEUROPROTECTION MARKET SIZE, BY SEVERE STAGE ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL NEUROPROTECTION MARKET SIZE, BY RELAPSING REMITTING MULTIPLE SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL NEUROPROTECTION MARKET SIZE, BY SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL NEUROPROTECTION MARKET SIZE, BY POSTURAL INSTABILITY PARKINSON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL NEUROPROTECTION MARKET SIZE, BY TREMOR DOMINANT PARKINSON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL NEUROPROTECTION MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL NEUROPROTECTION MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL NEUROPROTECTION MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL NEUROPROTECTION MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL NEUROPROTECTION MARKET SIZE, BY STROKE, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL NEUROPROTECTION MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL NEUROPROTECTION MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL NEUROPROTECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL NEUROPROTECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL NEUROPROTECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS NEUROPROTECTION MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS NEUROPROTECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS NEUROPROTECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS NEUROPROTECTION MARKET SIZE, BY STROKE, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS NEUROPROTECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES NEUROPROTECTION MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES NEUROPROTECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES NEUROPROTECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STROKE, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES NEUROPROTECTION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 209. CANADA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 210. CANADA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 211. CANADA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 212. CANADA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 213. CANADA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
TABLE 214. CANADA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
TABLE 215. CANADA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
TABLE 216. CANADA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2025-2030 (USD MILLION)
TABLE 217. CANADA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 218. CANADA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 219. CANADA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 220. CANADA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 221. CANADA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2024 (USD MILLION)
TABLE 222. CANADA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2025-2030 (USD MILLION)
TABLE 223. CANADA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 224. CANADA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 225. CANADA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 226. CANADA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 227. CANADA NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. CANADA NEUROPROTECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. CANADA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. CANADA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. CANADA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2024 (USD MILLION)
TABLE 232. CANADA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2025-2030 (USD MILLION)
TABLE 233. CANADA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
TABLE 234. CANADA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
TABLE 235. CANADA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 236. CANADA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 237. CANADA NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2024 (USD MILLION)
TABLE 238. CANADA NEUROPROTECTION MARKET SIZE, BY STROKE, 2025-2030 (USD MILLION)
TABLE 239. CANADA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. CANADA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. MEXICO NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 242. MEXICO NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 243. MEXICO NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 244. MEXICO NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 245. MEXICO NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
TABLE 246. MEXICO NEUROPROTECTION MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
TABLE 247. MEXICO NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
TABLE 248. MEXICO NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2025-2030 (USD MILLION)
TABLE 249. MEXICO NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 250. MEXICO NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 251. MEXICO NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 252. MEXICO NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 253. MEXICO NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2024 (USD MILLION)
TABLE 254. MEXICO NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2025-2030 (USD MILLION)
TABLE 255. MEXICO NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 256. MEXICO NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 257. MEXICO NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 258. MEXICO NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 259. MEXICO NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. MEXICO NEUROPROTECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. MEXICO NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. MEXICO NEUROPROTECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. MEXICO NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2024 (USD MILLION)
TABLE 264. MEXICO NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2025-2030 (USD MILLION)
TABLE 265. MEXICO NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
TABLE 266. MEXICO NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
TABLE 267. MEXICO NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 268. MEXICO NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 269. MEXICO NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2024 (USD MILLION)
TABLE 270. MEXICO NEUROPROTECTION MARKET SIZE, BY STROKE, 2025-2030 (USD MILLION)
TABLE 271. MEXICO NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. MEXICO NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL NEUROPROTECTION MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. BRAZIL NEUROPROTECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL NEUROPROTECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 295. BRAZIL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2024 (USD MILLION)
TABLE 296. BRAZIL NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2025-2030 (USD MILLION)
TABLE 297. BRAZIL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
TABLE 298. BRAZIL NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
TABLE 299. BRAZIL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 300. BRAZIL NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 301. BRAZIL NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2024 (USD MILLION)
TABLE 302. BRAZIL NEUROPROTECTION MARKET SIZE, BY STROKE, 2025-2030 (USD MILLION)
TABLE 303. BRAZIL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. BRAZIL NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. ARGENTINA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 306. ARGENTINA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 307. ARGENTINA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
TABLE 308. ARGENTINA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
TABLE 309. ARGENTINA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2018-2024 (USD MILLION)
TABLE 310. ARGENTINA NEUROPROTECTION MARKET SIZE, BY DRUGS, 2025-2030 (USD MILLION)
TABLE 311. ARGENTINA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2018-2024 (USD MILLION)
TABLE 312. ARGENTINA NEUROPROTECTION MARKET SIZE, BY NUTRACEUTICALS, 2025-2030 (USD MILLION)
TABLE 313. ARGENTINA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 314. ARGENTINA NEUROPROTECTION MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 315. ARGENTINA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2018-2024 (USD MILLION)
TABLE 316. ARGENTINA NEUROPROTECTION MARKET SIZE, BY ANTI INFLAMMATORY AGENTS, 2025-2030 (USD MILLION)
TABLE 317. ARGENTINA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2018-2024 (USD MILLION)
TABLE 318. ARGENTINA NEUROPROTECTION MARKET SIZE, BY ANTIOXIDANTS, 2025-2030 (USD MILLION)
TABLE 319. ARGENTINA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 320. ARGENTINA NEUROPROTECTION MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 321. ARGENTINA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 322. ARGENTINA NEUROPROTECTION MARKET SIZE, BY NMDA ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 323. ARGENTINA NEUROPROTECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 324. ARGENTINA NEUROPROTECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 325. ARGENTINA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 326. ARGENTINA NEUROPROTECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 327. ARGENTINA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2018-2024 (USD MILLION)
TABLE 328. ARGENTINA NEUROPROTECTION MARKET SIZE, BY ALZHEIMER'S DISEASE, 2025-2030 (USD MILLION)
TABLE 329. ARGENTINA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
TABLE 330. ARGENTINA NEUROPROTECTION MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
TABLE 331. ARGENTINA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2018-2024 (USD MILLION)
TABLE 332. ARGENTINA NEUROPROTECTION MARKET SIZE, BY PARKINSON'S DISEASE, 2025-2030 (USD MILLION)
TABLE 333. ARGENTINA NEUROPROTECTION MARKET SIZE, BY STROKE, 2018-2024 (USD MILLION)
TABLE 334. ARGENTINA NEUROPROTECTION MARKET SIZE, BY STROKE, 2025-2030 (USD MILLION)
TABLE 335. ARGENTINA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 336. ARGENTINA NEUROPROTECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 337. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 338. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 339. EUROPE, MIDDLE EAST & AFRICA NEUROPROTECTION MARKET SIZE, BY BIOLOGICS, 201

Samples

Loading
LOADING...

Companies Mentioned

  • Eli Lilly and Company
  • Roche Holding AG
  • Novartis AG
  • AstraZeneca PLC
  • Biogen Inc.
  • Pfizer Inc.
  • AbbVie Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • GlaxoSmithKline plc

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 336.31 Billion
Forecasted Market Value ( USD ) by 2030 $ 487.27 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Neuroprotection Therapeutics - Global Strategic Business Report - Product Image

Neuroprotection Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B. International Review of Neurobiology Volume 172 - Product Image

Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B. International Review of Neurobiology Volume 172

  • Book
  • Global
Mechanisms of Cell Death and Approaches to Neuroprotection/Disease Modification in Parkinson's Disease. International Review of Movement Disorders Volume 2 - Product Image

Mechanisms of Cell Death and Approaches to Neuroprotection/Disease Modification in Parkinson's Disease. International Review of Movement Disorders Volume 2

  • Book
  • Global
Indopathy for Neuroprotection: Recent Advances - Product Image

Indopathy for Neuroprotection: Recent Advances

  • Book
Hormones in Neurodegeneration, Neuroprotection, and Neurogenesis. Edition No. 1 - Product Image

Hormones in Neurodegeneration, Neuroprotection, and Neurogenesis. Edition No. 1

  • Book
  • 404 Pages

About the Neuroprotection Market

The Neuroprotection market within the context of Neurology Devices is focused on the development of products that protect the brain from damage caused by stroke, traumatic brain injury, and other neurological disorders. These products are designed to reduce the risk of long-term neurological damage and improve patient outcomes. Neuroprotection products include drugs, medical devices, and other therapies that can be used to reduce the risk of neurological damage. These products are used to reduce the risk of stroke, traumatic brain injury, and other neurological disorders. The Neuroprotection market is a rapidly growing segment of the Neurology Devices market, with a focus on improving patient outcomes and reducing the risk of long-term neurological damage. Companies in this market include Medtronic, Abbott, Boston Scientific, Stryker, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.